Equities

Transmedics Group Inc

Transmedics Group Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)75.56
  • Today's Change-3.79 / -4.77%
  • Shares traded2.14m
  • 1 Year change+9.58%
  • Beta2.0491
Data delayed at least 15 minutes, as of Nov 22 2024 20:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform6
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for TransMedics Group Inc have a median target of 115.00, with a high estimate of 179.00 and a low estimate of 87.00. The median estimate represents a 44.95% increase from the last price of 79.34.
High125.6%179.00
Med44.9%115.00
Low9.7%87.00

Earnings history & estimates in USD

On Oct 28, 2024, TransMedics Group Inc reported 3rd quarter 2024 earnings of 0.12 per share.
The next earnings announcement is expected on Feb 24, 2025.
Average growth rate+41.98%
TransMedics Group Inc reported annual 2023 losses of -0.77 per share on Feb 26, 2024.
Average growth rate+18.36%
More ▼

Revenue history & estimates in USD

TransMedics Group, Inc. had 3rd quarter 2024 revenues of 108.76m. This missed the 115.00m consensus estimate of the 9 analysts following the company. This was 161.73% above the prior year's 3rd quarter results.
Average growth rate+13.67%
TransMedics Group, Inc. had revenues for the full year 2023 of 241.62m. This was 158.53% above the prior year's results.
Average growth rate+98.50%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.